SG11202007726RA - Pharmaceutical compound, salts thereof, formulations thereof, and methods of making and using same - Google Patents
Pharmaceutical compound, salts thereof, formulations thereof, and methods of making and using sameInfo
- Publication number
- SG11202007726RA SG11202007726RA SG11202007726RA SG11202007726RA SG11202007726RA SG 11202007726R A SG11202007726R A SG 11202007726RA SG 11202007726R A SG11202007726R A SG 11202007726RA SG 11202007726R A SG11202007726R A SG 11202007726RA SG 11202007726R A SG11202007726R A SG 11202007726RA
- Authority
- SG
- Singapore
- Prior art keywords
- formulations
- salts
- making
- methods
- same
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018075023 | 2018-02-02 | ||
| PCT/US2019/016386 WO2019152863A1 (en) | 2018-02-02 | 2019-02-01 | Pharmaceutical compound, salts thereof, formulations thereof, and methods of making and using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202007726RA true SG11202007726RA (en) | 2020-09-29 |
Family
ID=65494537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202007726RA SG11202007726RA (en) | 2018-02-02 | 2019-02-01 | Pharmaceutical compound, salts thereof, formulations thereof, and methods of making and using same |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20200361933A1 (ja) |
| EP (1) | EP3746441B1 (ja) |
| JP (2) | JP7372926B2 (ja) |
| KR (1) | KR20200118098A (ja) |
| CN (2) | CN112105616B (ja) |
| AR (1) | AR114090A1 (ja) |
| AU (2) | AU2019215172B2 (ja) |
| BR (1) | BR112020015759A2 (ja) |
| CA (1) | CA3090270A1 (ja) |
| ES (1) | ES2949662T3 (ja) |
| HR (1) | HRP20230645T1 (ja) |
| IL (2) | IL312673A (ja) |
| MX (2) | MX2020008076A (ja) |
| PL (1) | PL3746441T3 (ja) |
| SG (1) | SG11202007726RA (ja) |
| SI (1) | SI3746441T1 (ja) |
| TW (2) | TW202426448A (ja) |
| WO (1) | WO2019152863A1 (ja) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3160410A1 (en) | 2019-12-04 | 2021-06-10 | Idorsia Pharmaceuticals Ltd | Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases |
| CN114129517A (zh) * | 2020-09-03 | 2022-03-04 | 苏州爱科百发生物医药技术有限公司 | 一种ak3287制剂及其制备方法和应用 |
| CN116509850A (zh) * | 2022-01-21 | 2023-08-01 | 苏州爱科百发生物医药技术有限公司 | N-芳基吡啶酮类化合物在尘肺治疗中的用途 |
| WO2023219106A1 (ja) * | 2022-05-10 | 2023-11-16 | Ｍｙｒｏｄｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ株式会社 | ２－メチル－２－チアゾリンの塩 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1176956T3 (da) * | 1999-05-07 | 2008-05-26 | Encysive Pharmaceuticals Inc | Carboxylsyrederivater, som inhiberer bindingen af integriner til deres receptorer |
| BRPI0720862A2 (pt) * | 2006-12-27 | 2014-02-25 | Sanofi Aventis | Derivados de isoquinolina e isoquinolinona substituídos como inibidores de rho-cinase |
| AP2011005824A0 (en) * | 2009-01-26 | 2011-08-31 | Intermune Inc | Methods for treating acute myocardial infarctions and associated disorders. |
| WO2011055270A1 (en) * | 2009-11-04 | 2011-05-12 | Wyeth Llc | Indole based receptor crth2 antagonists |
| AR092742A1 (es) * | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| KR102373700B1 (ko) * | 2014-04-02 | 2022-03-11 | 인터뮨, 인크. | 항섬유성 피리디논 |
| PL3383397T3 (pl) * | 2015-12-02 | 2021-12-27 | Merck Sharp & Dohme Corp. | Kompozycje farmaceutyczne zawierające dorawirynę, fumaran dizoproksylu tenofowiru i lamiwudynę |
-
2019
- 2019-02-01 CA CA3090270A patent/CA3090270A1/en active Pending
- 2019-02-01 IL IL312673A patent/IL312673A/en unknown
- 2019-02-01 CN CN201980014188.6A patent/CN112105616B/zh active Active
- 2019-02-01 SG SG11202007726RA patent/SG11202007726RA/en unknown
- 2019-02-01 HR HRP20230645TT patent/HRP20230645T1/hr unknown
- 2019-02-01 TW TW113105119A patent/TW202426448A/zh unknown
- 2019-02-01 AR ARP190100236A patent/AR114090A1/es unknown
- 2019-02-01 EP EP19706097.3A patent/EP3746441B1/en active Active
- 2019-02-01 US US16/966,384 patent/US20200361933A1/en not_active Abandoned
- 2019-02-01 ES ES19706097T patent/ES2949662T3/es active Active
- 2019-02-01 BR BR112020015759-7A patent/BR112020015759A2/pt unknown
- 2019-02-01 WO PCT/US2019/016386 patent/WO2019152863A1/en active Application Filing
- 2019-02-01 MX MX2020008076A patent/MX2020008076A/es unknown
- 2019-02-01 PL PL19706097.3T patent/PL3746441T3/pl unknown
- 2019-02-01 JP JP2020541912A patent/JP7372926B2/ja active Active
- 2019-02-01 IL IL276430A patent/IL276430B2/en unknown
- 2019-02-01 TW TW108104308A patent/TWI834634B/zh active
- 2019-02-01 CN CN202311023046.0A patent/CN117247383A/zh active Pending
- 2019-02-01 SI SI201930569T patent/SI3746441T1/sl unknown
- 2019-02-01 KR KR1020207025151A patent/KR20200118098A/ko not_active Application Discontinuation
- 2019-02-01 AU AU2019215172A patent/AU2019215172B2/en active Active
-
2020
- 2020-07-30 MX MX2020011756A patent/MX2020011756A/es unknown
-
2023
- 2023-08-02 JP JP2023126415A patent/JP2023145680A/ja active Pending
- 2023-08-31 AU AU2023222929A patent/AU2023222929A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL312673A (en) | 2024-07-01 |
| US20200361933A1 (en) | 2020-11-19 |
| AU2023222929A1 (en) | 2023-09-21 |
| AR114090A1 (es) | 2020-07-22 |
| IL276430B1 (en) | 2024-06-01 |
| ES2949662T3 (es) | 2023-10-02 |
| MX2020011756A (es) | 2021-06-23 |
| EP3746441B1 (en) | 2023-04-05 |
| SI3746441T1 (sl) | 2023-08-31 |
| CN112105616A (zh) | 2020-12-18 |
| EP3746441A1 (en) | 2020-12-09 |
| JP2021512118A (ja) | 2021-05-13 |
| TW201940482A (zh) | 2019-10-16 |
| TWI834634B (zh) | 2024-03-11 |
| MX2020008076A (es) | 2020-09-24 |
| IL276430A (en) | 2020-09-30 |
| AU2019215172B2 (en) | 2023-08-10 |
| CN112105616B (zh) | 2023-09-01 |
| AU2019215172A1 (en) | 2020-08-20 |
| CN117247383A (zh) | 2023-12-19 |
| BR112020015759A2 (pt) | 2020-12-08 |
| WO2019152863A1 (en) | 2019-08-08 |
| CA3090270A1 (en) | 2019-08-08 |
| JP7372926B2 (ja) | 2023-11-01 |
| IL276430B2 (en) | 2024-10-01 |
| KR20200118098A (ko) | 2020-10-14 |
| TW202426448A (zh) | 2024-07-01 |
| PL3746441T3 (pl) | 2023-07-31 |
| HRP20230645T1 (hr) | 2023-09-29 |
| JP2023145680A (ja) | 2023-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279464A (en) | Pharmaceutical formulation of odevixibat | |
| HK1247822A1 (zh) | 用於活性劑口服給藥的製劑 | |
| IL276430A (en) | A pharmaceutical compound, its cures, its formulations, and methods for its preparation and use | |
| ZA201908454B (en) | Solid preparation of cariprazine for oral administration | |
| IL275639A (en) | Formulation for RNA administration | |
| IL289763A (en) | Compounds, pharmaceutical compounds and methods for preparing compounds and their use | |
| EP3438105A4 (en) | DIARYL-BETA-LACTAM COMPOUND AND METHOD OF MANUFACTURE AND PHARMACEUTICAL USE THEREOF | |
| PH12017502376B1 (en) | Oral solid formulation containing irinotecan and method of preparing the same | |
| IL264880A (en) | Preparations for oral administration of active substances | |
| ZA202006570B (en) | Pharmaceutical formulations | |
| EP3647313A4 (en) | SUBSTITUTED ARYLETHER COMPOUND, PROCESS FOR PREPARATION, PHARMACEUTICAL COMPOSITION AND USE | |
| EP3497077A4 (en) | AMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHODS OF USE | |
| EP3785713A4 (en) | CETAGLIPTINE SALT, METHOD OF MANUFACTURING IT, PHARMACEUTICAL COMPOSITION AND USE OF IT | |
| PT3632436T (pt) | Composição farmacêutica compreendendo sais de lenvatinib | |
| IL283593A (en) | Bernaflam oral preparations | |
| IL282343A (en) | soluble medicinal compounds | |
| SG11202010792TA (en) | Improved pharmaceutical formulations | |
| EP3612185A4 (en) | PHARMACEUTICAL COMPOSITIONS WITH POH DERIVATIVES AND METHODS OF APPLICATION | |
| IL284132A (en) | A pharmaceutical compound, a method for its preparation and its use as a medicinal substance | |
| HUE062682T2 (hu) | Ibuprofén tartalmú orális gyógyszerészeti készítmény | |
| PT3778609T (pt) | Derivados de penama ou sais dos mesmos, composições farmacêuticas e utilização das mesmas | |
| EP3624788A4 (en) | FORMULATIONS OF HOMOTAURINS AND THEIR SALTS | |
| EP3666767A4 (en) | PYRIDAZINONE COMPOUND, PROCESS FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
| HUP1600415A2 (en) | Pimavanserin salts for the manufacture of pharmaceutical formulations | |
| EP3747866A4 (en) | BENZAMIDE COMPOUND AND MANUFACTURING METHOD, USE AND PHARMACEUTICAL COMPOSITION THEREOF |